A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies

Table 1 Comparison of baseline clinical characteristics between the PEG and rhG-CSF groups

Clinical characteristic	PEG group N = 36 cases	rhG-CSF group N = 31 cases	Statistical value	P value
Age (year)	52(25–66)	47(15–63)	0.944	0.345
Sex			0.567	0.451
Male	63.9% (23/36)	54.8% (17/31)
Female	36.1% (13/36)	45.2% (14/31)
Classification of diseases			9.295	0.010
Acute Leukemia	5.6% (2/36)	32.3% (10/31)
Lymphoma	30.6% (11/36)	32.3% (10/31)
Plasma cell disease	63.9% (23/36)	35.5% (11/31)
ECOG score			0.105	0.746
0–1	70.6% (24/34)	74.2% (23/31)
2–4	29.4% (10/34)	25.8% (8/31)
BMI (kg/m²)	23.72 ± 3.18	24.98 ± 4.48	1.339	0.185
Lymphoma risk stratification			0.276	1.000
Low-intermediate	36.4% (4/11)	40.0% (4/10)
High	27.3% (3/11)	30.0% (3/10)
Unknown	36.4% (4/11)	30.0% (3/10)
MM ISS stage			1.168	0.565
I	36.4% (8/22)	36.4% (4/11)
II	50.0% (11/22)	36.4% (4/11)
III	13.6% (3/22)	27.3% (3/11)
Number of chemotherapy cycles			3.656	0.056
< 5	55.6% (20/36)	32.3% (10/31)
≥ 5	44.4% (16/36)	67.7% (21/31)
Lenalidomide exposure			6.804	0.009
Yes	50.0% (18/36)	19.4% (6/31)
No	50.0% (18/36)	80.6% (25/31)
Premobilization disease status			0.083	0.773
Newly diagnosed	77.8% (28/36)	80.6% (25/31)
Remission after recurrence	22.2% (8/36)	19.4% (6/31)
Premobilization disease response			0.844	0.656
CR	50.0% (15/30)	62.5% (15/24)
VGPR	33.3% (10/30)	25.0% (6/24)
PR	16.7% (5/30)	12.5% (3/24)
Combination chemotherapy			14.374	0.000
Yes	5.6% (2/36)	45.2% (14/31)
No	94.4% (34/36)	54.8% (17/31)
Combination plerixafor			3.229	0.072
Yes	63.9% (23/36)	41.9% (13/31)
No	36.1% (13/36)	58.1% (18/31)

rhG-CSF, recombinant human granulocyte colony stimulating factor; PEG group, Mobilization of hematopoietic stem cells with mecapegfilgrastim; BMI, body mass index; MM, multiple myeloma; CR, complete response, PR, partial response, VGPR, very good partial response

ISSN: 1471-2407